Impact BioMedical, INC. Financing Receivable, after Allowance for Credit Loss
Impact BioMedical, INC. (IBO) had Financing Receivable, after Allowance for Credit Loss of $197.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets
us-gaap:NotesReceivableNet · last filed 2026-08-07
- 2026-06-30: Financing Receivable, after Allowance for Credit Loss $197.00K.
- 2026-03-31: Financing Receivable, after Allowance for Credit Loss $199.00K.
- 2025-12-31: Financing Receivable, after Allowance for Credit Loss $198.00K.
- 2025-06-30: Financing Receivable, after Allowance for Credit Loss $197.00K.
| Period end | Financing Receivable, after Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $197.00K 10-Q · filed 2026-08-07 |
| 2026-03-31 | $199.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $198.00K 10-Q · filed 2026-08-07 |
| 2025-06-30 | $197.00K 10-Q · filed 2026-08-07 |
| 2024-12-31 | $201.00K 10-K · filed 2026-03-11 |
| 2024-09-30 | $201.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $202.00K 10-Q · filed 2024-08-13 |
| 2023-12-31 | $203.00K 10-Q · filed 2024-11-12 |
| 2022-12-31 | $206.00K 10-K · filed 2024-02-20 |
| 2021-02-19 | $206.00K 10-Q · filed 2026-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |